While patients with such tumors are often excluded from clinical trials of novel agents such as immune checkpoint inhibitors, the recent FDA-approvals of anti-PD-L1 and anti-PD1 antibodies for patients with bladder cancer should facilitate future biomarker studies to determine how the lineage plasticity observed in other histologic variants impacts the tumor microenvironment. Here, CD274 is linked to urinary bladder carcinoma.